Pedro Berraondo López-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2022

  1. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  2. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96

2021

  1. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2016

  1. Innate immune mediators in cancer: between defense and resistance

    Immunological Reviews, Vol. 274, Núm. 1, pp. 290-306

2011

  1. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118